Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study

Mass General Brigham

Status and phase: Terminated; Phase 4

Conditions: Healthy; Pain; Pregnancy

Treatments: Drug: Hydromorphone 25mcg; Drug: Hydromorphone 100mcg; Drug: spinal anesthesia; Drug: Hydromorphone 50mcg

Study type: Interventional

Funder types: Other

Identifiers

NCT01943565

Hydromorphone_IT (Other Identifier)

2013P001850

Details and patient eligibility

About

Pain relief after cesarean delivery can be provided in a few ways. Most commonly, certain medications called opioids, such as morphine, are given through the vein or into the muscle. However, a more effective way to give pain relief with fewer side effects (such as nausea and slowing your breathing) is to give opioids in the spinal space as part of the medications given for a cesarean delivery.

For many years, the opioid of choice was morphine due to its long anesthetic effect and acceptable side effect profile. A nation-wide disruption in the supply of preservative-free morphine has made it necessary to look for alternatives. Many institutions worldwide have used another opioid, called hydromorphone, in the spinal space for over a decade. This drug has a very good safety and side effect profile and has been used at the investigators' institution for more than a year. Of interest, while a number of different doses of hydromorphone have been used, there have been very few studies to evaluate the best dose for providing good pain relief with minimal side effects. The goal of this study is to find the best dose of spinal hydromorphone for women undergoing cesarean delivery.

Full description

Intrathecal opioids in have been shown to produce analgesia. Lipid solubility and effect on specific mu opioid receptors in the dorsal horn of the spinal cord primarily determine the analgesic effect of intrathecally injected opioids. Rostral spread of intrathecal opioids causes some of the side effects like pruritus, respiratory depression, nausea and vomiting.

In the investigators' institute, during cesarean delivery under spinal anesthesia is usually performed with 1.6-1.8 ml of 0.75% bupivacaine with dextrose (hyperbaric solution) with 10-20mcg of fentanyl. Preservative free intrathecal (IT) morphine100 to 200 mcg is injected at the time of initiation of spinal block for postoperative pain relief. Multiple studies have shown excellent postoperative pain relief following cesarean delivery up to 18hrs with this dosing regimen.

However, there has been a national shortage of preservative free morphine since August 2012. Based on the pharmacokinetic and pharmacodynamic profile, intrathecal (IT) preservative free hydromorphone 100 mcg has been used as a substitute. Anecdotal experience during the past 8 months suggest that patients have comparable post partum pain relief, with a similar side-effect profile to IT morphine.

There is no published data on the optimal dose of IT hydromorphone for post cesarean analgesia. There are case reports and retrospective case study of use of 100mcg IT hydromorphone. One randomized controlled trial for knee arthroscopy used 2.5-5-10 mcg of IT hydromorphone for postoperative analgesia.

Hence it is important to determine the optimal dose of IT hydromorphone for post operative pain management following cesarean delivery in terms of analgesic efficacy, incidence of side effects and the need for treatment interventions

This study will aim to determine the optimal dose of intrathecal hydromorphone that would provide adequate postoperative analgesia with minimal side effects.

Enrollment: 29 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy at-term parturients undergoing elective cesarean delivery under spinal anesthesia

Exclusion criteria

• Emergency cesarean delivery
• Respiratory disease
• significant comorbidities: preeclampsia, insulin-dependent diabetes mellitus
• obstructive sleep apnea
• body mass index > 35kg/m2
• <18yrs
• documented intolerance or allergy to systemic or neuraxial opioids
• patient with a history of chronic opioid or current use of opioids

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

29 participants in 3 patient groups

Hydromorphone 25mcg

Active Comparator group

Description:

The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia

Treatment:

Drug: Hydromorphone 25mcg

Drug: spinal anesthesia

Hydromorphone 50mcg

Active Comparator group

Description:

The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia

Treatment:

Drug: Hydromorphone 50mcg

Drug: spinal anesthesia

Hydromorphone 100mcg

Active Comparator group

Description:

The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia

Treatment:

Drug: Hydromorphone 100mcg

Drug: spinal anesthesia